MNK Stock Price Chart More Charts

MNK Price/Volume Stats

Mallinckrodt plc Ordinary Shares (MNK) Company Bio

Mallinckrodt Public Limited Company is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology, neonatal critical care respiratory therapies, and analgesics and central nervous system drugs. The company was founded in 2013 and is based in Dublin, Ireland.

MNK Price Forecast Based on DCF Valuation

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Mallinckrodt plc. To summarize, we found that Mallinckrodt plc ranked in the 87th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. As for the metrics that stood out in our discounted cash flow analysis of Mallinckrodt plc, consider:

• 8% of the company's capital comes from equity, which is greater than only 1.87% of stocks in our cash flow based forecasting set.
• Mallinckrodt plc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -11.5. This coverage rate is greater than that of only 5.88% of stocks we're observing for the purpose of forecasting via discounted cash flows.
• The weighted average cost of capital for the company is 18. This value is greater than 98.02% stocks in the Healthcare sector that generate free cash flow.

TYHT, INCY, THC, STAA, and LNTH can be thought of as valuation peers to MNK, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.